Abstract
Choroidal neovascularization (CNV) is the growth of abnormal blood vessels in the choroid layer of the eye; it is a pathophysiological characteristic of wet age-related macular degeneration (AMD). Current clinical treatment utilizes frequent intravitreal injections, which can result in retinal detachment and increased ocular pressure. The purpose of the current study is to develop a novel drug delivery system of loteprednol etabonateencapsulated PEGylated PLGA nanoparticles incorporated into the PLGA-PEG-PLGA thermoreversible gel for treatment of AMD. The proposed drug delivery system was characterized for drug release, cytotoxicity studies and vascular endothelial growth factor (VEGF) suppression efficacy studies using ARPE-19 cells. The nanoparticles showed uniform size distribution with mean size of 168.60±23.18 nm and exhibited sustained drug release. Additionally, the proposed drug delivery system was non-cytotoxic to ARPE-19 cells and significantly reduced VEGF expression as compared to loteprednol etabonate solution. These results suggest the proposed drug delivery system can be used for further work in an animal model of experimental AMD with reduced intravitreal administration frequency.
Keywords: Choroidal neovascularization, loteprednol etabonate, PLGA nanoparticles, thermoreversible gel, VEGF.
Pharmaceutical Nanotechnology
Title:Efficacy of Loteprednol Etabonate Drug Delivery System in Suppression of in vitro Retinal Pigment Epithelium Activation
Volume: 2 Issue: 4
Author(s): Anjali Hirani, Yong W. Lee, Yashwant Pathak and Vijaykumar Sutariya
Affiliation:
Keywords: Choroidal neovascularization, loteprednol etabonate, PLGA nanoparticles, thermoreversible gel, VEGF.
Abstract: Choroidal neovascularization (CNV) is the growth of abnormal blood vessels in the choroid layer of the eye; it is a pathophysiological characteristic of wet age-related macular degeneration (AMD). Current clinical treatment utilizes frequent intravitreal injections, which can result in retinal detachment and increased ocular pressure. The purpose of the current study is to develop a novel drug delivery system of loteprednol etabonateencapsulated PEGylated PLGA nanoparticles incorporated into the PLGA-PEG-PLGA thermoreversible gel for treatment of AMD. The proposed drug delivery system was characterized for drug release, cytotoxicity studies and vascular endothelial growth factor (VEGF) suppression efficacy studies using ARPE-19 cells. The nanoparticles showed uniform size distribution with mean size of 168.60±23.18 nm and exhibited sustained drug release. Additionally, the proposed drug delivery system was non-cytotoxic to ARPE-19 cells and significantly reduced VEGF expression as compared to loteprednol etabonate solution. These results suggest the proposed drug delivery system can be used for further work in an animal model of experimental AMD with reduced intravitreal administration frequency.
Export Options
About this article
Cite this article as:
Hirani Anjali, W. Lee Yong, Pathak Yashwant and Sutariya Vijaykumar, Efficacy of Loteprednol Etabonate Drug Delivery System in Suppression of in vitro Retinal Pigment Epithelium Activation, Pharmaceutical Nanotechnology 2014; 2 (4) . https://dx.doi.org/10.2174/2211738503666150327002434
DOI https://dx.doi.org/10.2174/2211738503666150327002434 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) Novel Antitumor Strategies Using Cytokine PEDF for Prostate Cancer Therapy
Current Angiogenesis (Discontinued) <i>In vitro</i> and <i>In vivo</i> Toxicity Assessment of Metallic Nanoparticulate Systems for Skin Targeting
Current Nanotoxicity and Prevention (Discontinued) Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Cytokines in the Pathogenesis of Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Design T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Immunity to Tumour Antigens
Current Pharmaceutical Design Experimental Drugs for Neuropathic Pain
Current Neuropharmacology Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Anal Carcinoma
Current Cancer Therapy Reviews Regulation of Matrix Synthesis, Remodeling and Accumulation in Glomerulosclerosis
Current Pharmaceutical Design PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals
Current Drug Delivery COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry Applications of the Rare Earth Elements in Cancer Imaging and Therapy
Current Nanoscience